https://curiecapital.nl/wp-content/uploads/2020/06/001263_SiriusMedicalPR-CErelease.pdf
Stay informed about the latest updates from Curie Capital and the ongoing activities within our portfolio companies.
TGD001 is being developed to offer patients with clotting disorders a faster, safer and more effective treatment than today’s...
Financing co-led by Johnson & Johnson Innovation – JJDC, Inc., Forbion and Novartis Venture Fund Lead first-in-class product...
Amsterdam, Netherlands – 13 August 2024 – Pitchbook has recently awarded Curie Capital with a 5th place among Dutch Venture...
Learnings will be used in the clinical development programs of NET-targeting therapies such as Citryll’s lead...
• V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders...
OSS, the Netherlands, 13-02-2024 — Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat...